Expertise in
76
conditions

Dr. Rangaswamy A. Chintapatla

Hematology Oncology | Oncology
7360 West Deschutes Avenue, 
Kennewick, WA 
Accepting New Patients
Offers Telehealth
Expertise in
76
conditions
7360 West Deschutes Avenue, 
Kennewick, WA 

Overview

Rangaswamy Chintapatla is a Hematologist Oncology specialist and an Oncologist in Kennewick, Washington. Dr. Chintapatla is highly rated in 76 conditions, according to our data. His top areas of expertise are Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Myelodysplastic Syndrome (MDS), and Familial Colorectal Cancer. Dr. Chintapatla is currently accepting new patients.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology Oncology
Oncology

Licenses

Internal Medicine in WA

Hospital Affiliations

Good Shepherd Medical Center
Prosser Memorial Hospital
Kadlec Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

7360 West Deschutes Avenue, Kennewick, WA 99336

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Enrollment Status: Terminated
Publish Date: May 28, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

8 Total Publications

Addition of ADAMTS13 testing to cryptogenic stroke evaluation: index case and single-center screening initial experience.
Addition of ADAMTS13 testing to cryptogenic stroke evaluation: index case and single-center screening initial experience.
Journal: Blood advances
Published: July 16, 2025
Similar Doctors
Expertise in
62
conditions
Dr. Basir U. Haque
Hematology Oncology | Hematology
Expertise in
62
conditions
Dr. Basir U. Haque
Hematology Oncology | Hematology
7360 West Deschutes Avenue, 
Kennewick, WA 
 (2.2 miles away)
509-942-2540
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Basir Haque is a Hematologist Oncology specialist and a Hematologist in Kennewick, Washington. Dr. Haque is highly rated in 62 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Lynch Syndrome, Colorectal Cancer, and Thrombocytopenia. Dr. Haque is currently accepting new patients.

Expertise in
72
conditions
Dr. Eric O. Gamboa
Hematology Oncology | Hematology
Expertise in
72
conditions
Dr. Eric O. Gamboa
Hematology Oncology | Hematology
7360 West Deschutes Avenue, 
Kennewick, WA 
 (2.2 miles away)
509-942-2540
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Gamboa is a Hematologist Oncology specialist and a Hematologist in Kennewick, Washington. Dr. Gamboa is highly rated in 72 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), and Colorectal Cancer. Dr. Gamboa is currently accepting new patients.

Expertise in
38
conditions
Dr. Nattamol Hosiriluck
Oncology | Hematology
Expertise in
38
conditions
Dr. Nattamol Hosiriluck
Oncology | Hematology
7360 West Deschutes Avenue, 
Kennewick, WA 
 (2.2 miles away)
509-942-2540
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nattamol Hosiriluck is a Hematologist and an Oncologist in Kennewick, Washington. Dr. Hosiriluck is highly rated in 38 conditions, according to our data. Her top areas of expertise are Neuroendocrine Tumor, Upper Tract Urothelial Carcinoma (UTUC), Colorectal Cancer, and Familial Colorectal Cancer. Dr. Hosiriluck is currently accepting new patients.

Frequently Asked Questions about Dr. Rangaswamy A. Chintapatla

How do I make an appointment with Dr. Rangaswamy A. Chintapatla?

You can book an appointment with Dr. Rangaswamy A. Chintapatla by calling their office at 509-942-2540. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rangaswamy A. Chintapatla a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rangaswamy A. Chintapatla is classified as an Distinguished expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rangaswamy A. Chintapatla specialize in?

While Dr. Rangaswamy A. Chintapatla is a Hematology Oncology, they have specific expertise in Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Myelodysplastic Syndrome (MDS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Rangaswamy A. Chintapatla participate in research or clinical trials?

Yes. Dr. Rangaswamy A. Chintapatla has published 8 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Dr. Rangaswamy A. Chintapatla's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rangaswamy A. Chintapatla accept my insurance?

Dr. Rangaswamy A. Chintapatla accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 509-942-2540 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chintapatla's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 63 Advanced Conditions
    View All 127 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile